Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
Status:
Completed
Trial end date:
2019-09-13
Target enrollment:
Participant gender:
Summary
This partially randomized phase I/II trial studies the side effects and best dose of anakinra
when given together with lenalidomide and dexamethasone in treating patients with early stage
multiple myeloma. Biological therapies, such as lenalidomide and anakinra, may stimulate or
suppress the immune system in different ways and stop cancer cells from growing. Drugs used
in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. It is not yet known whether lenalidomide and dexamethasone are more effective with
or without anakinra in treating patients with multiple myeloma.